TRACON Pharmaceuticals, Inc.
OTC: TCON0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Craig R. Jalbert CIRA
- Employees
- 17
- Headquarters
- San Diego, United States
- IPO year
- 2015
- Market cap
- $109.7K
- Website
- https://www.traconpharma.com
Loading TCON…
Loading profile data…Frequently asked questions about TCON
What does TRACON Pharmaceuticals, Inc. (TCON) do?
TRACON Pharmaceuticals, Inc. functions as a biopharmaceutical enterprise, primarily dedicated to the discovery, development, and eventual market launch of cancer treatments within the United States. Its current product pipeline features several assets in various stages of clinical trials. These include envafolimab (KN035), a PD-L1 single-domain...
Where does TCON trade?
TRACON Pharmaceuticals, Inc. (TCON) trades on the Other OTC.
What sector is TCON in?
TRACON Pharmaceuticals, Inc. (TCON) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of TRACON Pharmaceuticals, Inc.?
Craig R. Jalbert CIRA is the chief executive officer of TRACON Pharmaceuticals, Inc. (TCON).
Where is TRACON Pharmaceuticals, Inc. headquartered?
TRACON Pharmaceuticals, Inc. is headquartered in United States.
Does TCON pay a dividend?
TRACON Pharmaceuticals, Inc. (TCON) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did TCON go public?
TRACON Pharmaceuticals, Inc. (TCON) completed its initial public offering in 2015.